Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.
about
Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitusEffect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.Long-term treatment of patients with HIV-1: the role of atazanavirMetabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.Antiretroviral drugs: critical issues and recent advancesMetabolic complications and treatment of perinatally HIV-infected children and adolescents.Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
P2860
Q28222271-8D4761F0-320C-47C2-BB52-20548C853927Q33787957-B0C6E24D-2CF1-41A9-BBFB-8E85D629540DQ33918414-5AD2B5A3-86D8-460C-83A4-69C11C61E077Q34730407-ECE2C630-ECAB-4372-82BF-F67521CB0BAFQ35012924-05796668-A7FB-40C7-A5FA-3B85A4A05FFCQ35557219-BD499C29-30D5-4D77-B20F-7C0D11083B75Q35945312-5D9A2FAA-8B3F-4033-836C-0B9AAF1BA58BQ35963960-9A071EC2-6A9D-4395-8842-8A9DF68D82FDQ36020992-144280E9-B661-4567-9CB5-1874A6B9B7EDQ36952291-AE852B28-B3E5-446B-9B2C-D435B2D954C1Q37242966-F02A7F99-265F-48B8-A9A4-0166F9CEF46DQ37319195-E92171FF-5AB3-4452-812C-EC7BA8FC6F3AQ58713369-505407D4-7AB7-4964-ABC5-7387001F3C00
P2860
Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@en
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@nl
type
label
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@en
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@nl
prefLabel
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@en
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@nl
P2093
P1476
Switching to atazanavir improv ...... ts with severe hyperlipidemia.
@en
P2093
Brigitte Castro-Frenzel
Esther Voigt
Georg M N Behrens
Jörg-Andres Rump
Margrit Lubach-Ruitman
Matthias Stoll
Reinhold E Schmidt
Stefan Christensen
Stefan Esser
Ulrike Möbius
P304
P407
P577
2005-06-01T00:00:00Z